Verve Therapeutics to Participate in Upcoming Investor Conferences
30 Maggio 2024 - 10:01PM
Verve Therapeutics, a clinical-stage biotechnology company
pioneering a new approach to the care of cardiovascular disease
with single-course gene editing medicines, today announced that
management will participate in fireside chats during the following
investor conferences:
- Jefferies Global Healthcare Conference on Thursday, June 6,
2024, at 1 p.m. ET in New York, NY
- Goldman Sachs 45th Annual Global Healthcare Conference on
Monday, June 10, 2024, at 8 a.m. ET in Miami Beach, FL
Live webcasts will be available in the investor section of the
company's website at www.vervetx.com, and will be archived for 30
days following the fireside chats.
About Verve Therapeutics Verve
Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic
medicines company pioneering a new approach to the care of
cardiovascular disease, potentially transforming treatment from
chronic management to single-course gene editing medicines. The
company’s lead programs – VERVE-101, VERVE-102, and VERVE-201 –
target genes that have been extensively validated as targets for
lowering low-density lipoprotein cholesterol (LDL-C), a root cause
of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and
VERVE-102 are designed to permanently turn off the PCSK9 gene in
the liver and are being developed initially for heterozygous
familial hypercholesterolemia (HeFH) and ultimately to treat
patients with established ASCVD who continue to be impacted by high
LDL-C levels. VERVE-201 is designed to permanently turn off the
ANGPTL3 gene in the liver and is initially being developed for
homozygous familial hypercholesterolemia (HoFH) and for refractory
hypercholesterolemia where patients still have high LDL-C despite
treatment with maximally-tolerated standard of care therapies. For
more information, please visit www.VerveTx.com.
Investor ContactJen RobinsonVerve Therapeutics,
Inc.jrobinson@vervetx.com
Media ContactAshlea
Kosikowski1ABashlea@1abmedia.com
Grafico Azioni Verve Therapeutics (NASDAQ:VERV)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Verve Therapeutics (NASDAQ:VERV)
Storico
Da Giu 2023 a Giu 2024